GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Short Percentage of Float

Proteomics International Laboratories (ASX:PIQ) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Proteomics International Laboratories's Short Percentage of Float

For the Biotechnology subindustry, Proteomics International Laboratories's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteomics International Laboratories's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's Short Percentage of Float falls into.


;
;

Proteomics International Laboratories Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories Headlines

No Headlines